ClinicalTrials.gg
RecruitingNCT07161583Updated Sep 11, 2026

Advanta VXT and Flixene PMCF Registry

An observational study in Peripheral Arterial Disease, sponsored by Atrium Medical Corporation. Recruiting at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-11.

Sponsored by Atrium Medical Corporation · Observational

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
1,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 479 studies in Peripheral Arterial Disease with a site in United States — 82 open to participants now, 101 under way, 10 of them phase 3. Peripheral Arterial Disease · United States.

Planned enrollment
18th of 103
1,000 · median 125
Started
2025
with 21 others
Observational
104 of 479
19 open now
Primary completion
2027-12
later than 62 of 100 live
Registered
456th of 479
by date

Among the 479 studies in Peripheral Arterial Disease with a site in United States, this one is the 18th largest by planned enrollment of the 103 observational ones that give a count, is one of 22 that started in 2025, is one of 104 observational ones, reaches primary completion later than 62 of the 100 other live ones, and was the 456th registered.

Peripheral Arterial Disease

1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.

Browse Peripheral Arterial Disease studies →

Open to participants now

82 of the 479 studies in Peripheral Arterial Disease with a site in United States are open now. Recruiting first, the newest first:

76 more — sign in →

All 82 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 479 studies in Peripheral Arterial Disease with a site in United States, or all of them as a file.
02

Study summary

The purpose of the registry is to evaluate the long-term safety and performance of Advanta VXT and Flixene vascular grafts for repair or replacement of peripheral arteries. This registry is also intended to provide further data on the clinical usefulness of the Advanta VXT and Flixene vascular grafts.

03

Conditions studied

  • Peripheral Arterial Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

An approximate 1,000 patients from 25 sites across the US and Europe will participate in this registry. The number of patients and sites included will ensure a representation of the overall population, specifically in vascular surgery. No mandated procedures, assessments or visits will be implemented, given the non-interventional nature of the registry.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willing, and able to provide legally-effective written (as required by IRB/EC)
  • Male and female patients that have undergone replacement or repair of the peripheral arteries using the Advanta VXT or Flixene vascular graft.
  • Were at least 18 years of age at the time of the procedure
  • Available records for data collection, with a minimum of 36 months of data/follow-up.

Exclusion criteria

Exclusion Criteria:

- Active infection in the region of graft placement at the time of implantation of the Advanta VXT or Flixene vascular graft

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
1,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Peripheral Arterial Disease (PAD) Cohort

    Device: Advanta VXT Vascular Graft · Device: Flixene Vascular Graft

Interventions

  • DeviceAdvanta VXT Vascular Graft

    The Advanta VXT graft is a two (2)-layer graft employing a single layer ePTFE graft, which is then wrapped with an additional layer of ePTFE for increased support. Some Advanta VXT configurations include Helix, which is a monofilament bead wrapped circumferentially around a portion or the entire length of the graft (such a graft is also called a Ringed Graft). The helix rings are bonded to the exterior surface of the graft. Advanta VXT Tapers are formed by changing the graft diameter, expanding from a small Inner Diameter (ID) to a larger ID (with the result that one end is larger).

  • DeviceFlixene Vascular Graft

    The Flixene vascular graft is a three (3)-layered graft comprised of ePTFE. The Flixene graft was designed with an additional layer of ePTFE. As a result of its design, ring support is not necessary

06

What researchers measure

Primary outcomes

  1. Percentage of Participants meeting Primary Efficacy Endpoint

    Primary patency defined as freedom from graft occlusion or reintervention

    Time frame: Procedure/surgery through registry completion (a minimum of 3 years)

  2. Percentage of Participants meeting Primary Safety Endpoint

    Major Adverse Limb Events (MALE), defined as major amputation or major reintervention, including placement of a new bypass graft, interposition graft, thrombectomy, or thrombolysis

    Time frame: Procedure/surgery through registry completion (a minimum of 3 years)

Secondary outcomes

  1. Incidence of Reported Complications/Events

    Time frame: Procedure/surgery through registry completion (a minimum of 3 years)

  2. Percentage of Participants meeting Primary-Assisted Graft Patency

    Defined as freedom from graft occlusion irrespective of whether an intervention was performed; in other words, primary-assisted patency is not lost when a reintervention is performed to preserve graft patency before occlusion occurs

    Time frame: Procedure/surgery through registry completion (a minimum of 3 years)

  3. Percentage of Participants meeting Secondary Graft Patency

    Defined as freedom from "permanent" loss of graft patency

    Time frame: Procedure/surgery through registry completion (a minimum of 3 years)

  4. Rate of change in Rutherford Category

    Time frame: Baseline, procedure/surgery, through registry completion (a minimum of 3 years)

  5. Rate of change in Ankle-Brachial Index (ABI)

    Time frame: Baseline, procedure/surgery, through registry completion (a minimum of 3 years)

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2025 (actual). Primary completion is estimated for Dec 2027, 27 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2025
First posted
Sep 8, 2025
StartActual
Sep 25, 2025
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Sep 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07161583
Lead sponsor
Atrium Medical Corporation
Responsible party
Sponsor
First posted
Sep 8, 2025
Start date
Sep 25, 2025
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Sep 11, 2026

Study contacts

Senior Manager, Clinical Affairs
Contact
kristen.nolin@getinge.com
+1 603 233 7685
Director, Clinical Affairs
study director · Getinge

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion